References
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
- Lee I. Advances in surgical approaches in glioblastoma (GBM). Chin Clin Oncol. 2017;6(4):42.
- Comet I, Riising EM, Leblanc B, et al. Maintaining cell identity: PRC2-mediated regulation of transcription and cancer. Nat Rev Cancer. 2016;16(12):803–810.
- Cao J, Pontes KC, Heijkants RC, et al. Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target. J Pathol. 2018;245(4):433–444.
- Mochizuki D, Misawa Y, Kawasaki H, et al. Aberrant epigenetic regulation in head and neck cancer due to distinct EZH2 overexpression and DNA hypermethylation. IJMS. 2018;19(12):3707.
- Ballare C, Lange M, Lapinaite A, et al. Phf19 links methylated Lys36 of histone H3 to regulation of Polycomb activity. Nat Struct Mol Biol. 2012;19(12):1257–1265.
- Qin S, Guo Y, Xu C, et al. Tudor domains of the PRC2 components PHF1 and PHF19 selectively bind to histone H3K36me3. Biochem Biophys Res Commun. 2013;430(2):547–553.
- Wang S, Robertson GP, Zhu J. A novel human homologue of Drosophila polycomblike gene is up-regulated in multiple cancers. Gene. 2004;343(1):69–78.
- Deng Q, Hou J, Feng L, et al. PHF19 promotes the proliferation, migration, and chemosensitivity of glioblastoma to doxorubicin through modulation of the SIAH1/β-catenin axis. Cell Death Dis. 2018;9(11):1049.
- Lu J, Ji H, Tang H, et al. microRNA-124a suppresses PHF19 over-expression, EZH2 hyper-activation, and aberrant cell proliferation in human glioma. Biochem Biophys Res Commun. 2018;503(3):1610–1617.
- Mason MJ, Schinke C, Eng CLP, et al. Multiple myeloma DREAM challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia. 2020. DOI:10.1038/s41375-020-0742-z
- Tao F, Tian X, Ruan S, et al. miR-211 sponges lncRNA MALAT1 to suppress tumor growth and progression through inhibiting PHF19 in ovarian carcinoma. FASEB J. 2018;32(11):6330–6343.
- Xu H, Hu YW, Zhao JY, et al. MicroRNA-195-5p acts as an anti-oncogene by targeting PHF19 in hepatocellular carcinoma. Oncol Rep. 2015;34(1):175–182.
- Ji Y, Fioravanti J, Zhu W, et al. miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8+ T cell fate. Nat Commun. 2019;10(1):2157.
- Wang H, Wu K, Sun Y, et al. STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro. BMB Rep. 2012;45(11):629–634.
- Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.
- Szasz AM, Lanczky A, Nagy A, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016;7(31):49322–49333.
- Ning F, Wang C, Niu S, et al. Transcription factor Phf19 positively regulates germinal center reactions that underlies its role in rheumatoid arthritis. Am J Transl Res. 2018;10(1):200–211.
- Faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer. Int J Mol Sci. 2015;16(9):21138–21152.
- Fu HW, Lin X, Zhu YX, et al. Circ-IGF1R has pro-proliferative and anti-apoptotic effects in HCC by activating the PI3K/AKT pathway. Gene. 2019;716:144031.
- Chen Z, Yu W, Zhou Q, et al. A novel lncRNA IHS promotes tumor proliferation and metastasis in HCC by regulating the ERK- and AKT/GSK-3β-signaling pathways. Mol Ther Nucleic Acids. 2019;16:707–720.
- Conway E, Healy E, Bracken AP. PRC2 mediated H3K27 methylations in cellular identity and cancer. Curr Opin Cell Biol. 2015;37:42–48.
- Pan MR, Hsu MC, Chen LT, et al. G9a orchestrates PCL3 and KDM7A to promote histone H3K27 methylation. Sci Rep. 2015;5:18709.
- Cai Z, Qian ZY, Jiang H, et al. hPCL3s promotes hepatocellular carcinoma metastasis by activating β-catenin signaling. Cancer Res. 2018;78(10):2536–2549.